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Abstract
Background: The complex interactions between recurrent trypsin-mediated pancreatic injury, alcohol-associated pancreatic
injury and SPINK1 polymorphisms in chronic pancreatitis (CP) are undefined. We hypothesize that CP occurs as a result of
multiple pathological mechanisms (pathways) that are initiated by different metabolic or environmental factors (etiologies)
and may be influenced differentially by downstream genetic risk factors. We tested this hypothesis by evaluating the
differences in effect size of the high risk SPINK1 N34S haplotype on CP from multiple etiologies after combining clinical
reports of SPINK1 N34S frequency using meta-analysis.
Methods and Findings: The Pubmed and the Embase databases were reviewed. We studied 24 reports of SPINK1 N34S in CP
(2,421 cases, 4,857 controls) using reported etiological factors as surrogates for pathways and multiple meta-analyses to
determine the differential effects of SPINK1 N34S between alcoholic and non-alcoholic etiologies. Using estimates of
between-study heterogeneity, we sub-classified our 24 studies into four specific clusters. We found that SPINK1 N34S is
strongly associated with CP overall (OR 11.00; 95% CI: 7.59–15.93), but the effect of SPINK1 N34S in alcoholic CP (OR 4.98,
95% CI: 3.16–7.85) was significantly smaller than in idiopathic CP (OR 14.97, 95% C.I. = 9.09–24.67) or tropical CP (OR 19.15,
95% C.I. = 8.83–41.56). Studies analyzing familial CP showed very high heterogeneity suggestive of a complex etiology with
an I2 = 80.95%.
Conclusion: The small effect of SPINK1 N34S in alcoholic subjects suggests that CP is driven through a different pathway
that is largely trypsin-independent. The results also suggest that large effect sizes of SPINK1 N34S in small candidate gene
studies in CP may be related to a mixture of multiple etiologic pathways leading to the same clinical endpoint.
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Introduction
Chronic pancreatitis (CP) is a common chronic inflammatory
syndrome of the pancreas that has been defined by clinical signs
and symptoms linked to end-stage pathological criteria[1]. While
acute pancreatitis is recognized as an acute inflammatory response
to pancreatic injury [2], the pathophysiological mechanisms
underlying the development and progression of CP in humans
have yet to be discerned.
CP is defined by the presence of chronic inflammatory cells
within the pancreas, progressive fibrosis, sclerosis and parenchy-
mal atrophy [1,3,4,5]. The pancreatic stellate cell (PSC) is the
mediator of fibrosis, and is ubiquitous in chronic pancreatitis [6,7].
The diagnosis of CP requires greater than six month duration of
inflammation, permanent loss of exocrine function, and evidence
on abdominal imaging studies of duct distortion, fibrosis or
calcification. Abdominal pain and diabetes mellitus are clinical
features that are also common to CP [1,3,4,5].
CP is sub-classified according to epidemiologic risk factors (e.g.
alcoholism, family history, living in certain tropical regions,
autoimmune disorders), although the relative risk of recognized
environmental factors may be diminutive [3,8]. If no inciting
factor can be identified, CP is termed ‘idiopathic’ and sub-
classified as early versus late-onset idiopathic CP by age of
diagnosis. Although excessive alcohol consumption is a risk factor
for CP, fewer than 5% of alcoholics develop pancreatitis, and
many patients with CP do not drink alcohol [8,9]. Furthermore,
the pathophysiological pathways that link the normal pancreas to
the end-stage pathology of CP have not been clearly defined.
Several recent human genetic studies have provided insight into
components of the pathogenic mechanisms leading to human CP,
all of which are related to failure to regulate intrapancreatic
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trypsin activity and the associated pancreatic injury. The three
primary susceptibility genes for CP include the cationic trypsin-
ogen gene (PRSS1) [10], the cystic fibrosis transmembrane
conductance regulator gene (CFTR) [11,12], and the pancreatic
secretory trypsin inhibitor gene, also known as serine protease
inhibitor Kazal type 1 (SPINK1) [13,14,15]. SPINK1 is an acute
phase protein whose gene expression and protein concentrations
are markedly upregulated by inflammation [16,17,18]. SPINK1
gene mutations are thought to diminish protection against
prematurely activated trypsin, and are thereby linked to trypsin-
related pancreatic injury [10,15]. PRSS1, CFTR and SPINK1
seem to play complementary roles in protecting the pancreas from
the damage incurred by prematurely activated trypsin.
The high-risk SPINK1 N34S haplotype has been observed in
one to three percent of most populations, while the incidence of
CP is less than one in ten thousand [14,19]. Furthermore, the
reported range of odds ratios (ORs) describing the risk of SPINK1
N34S carriers of developing pancreatitis has varied from non-
significance [13] to nearly 80 [15]. Wide variations in reported
effects of small genetic association studies have been attributed to
statistical variation in underpowered studies, poor methodology,
publication bias toward studies with large ORs as well as a myriad
of other non-biological factors [20,21,22]. However, we hypoth-
esize that in the case of the SPINK1 N34S high-risk haplotype, the
variation in reported effect sizes may be a result of differences in
the proportion of subjects with pathogenic pathways linking
environmental stressors to pancreatic stellate cell (PSC) activation
through recurrent trypsinogen activation and inadequate trypsin
inhibition by SPINK1. The basic model is illustrated in Figure 1.
In this model, SPINK1-regulated pathways would include all
upstream etiologic factors associated with recurrent trypsinogen
activation (e.g. PRSS1 and CFTR mutations) while SPINK1-
independent pathways would include factors that drive PSC to
produce fibrosis through mechanisms that are generally indepen-
dent of recurrent trypsinogen activation (e.g. autoimmune
pancreatitis, toxins, pancreatic cancer). Although a number of
functionally different risk factors have been statistically associated
with alcoholic CP [9], it is not clear if the PSC and fibrosis in
alcoholic CP is driven by trypsin-dependent, or independent
pathways.
In order to address questions of heterogeneity, and specifical-
ly the role of alcohol and SPINK1 N34S in human CP, we
employed meta-analysis in a manner illustrative of the growing
realization that meta-analysis is most effective in examining
relationships in complex diseases by evaluating between-study
heterogeneity [23,24,25]. We tested the hypothesis that the true
effect size of the functional SPINK1 N34S haplotype is pathway-
dependent by reviewing the world literature and gathering data from
case-control studies that evaluated the association of SPINK1 N34S
with CP. When possible, we reclassified patients by reported
etiology and performed a series of meta-analyses on each category
to determine the effect size of the high-risk SPINK1 N34S
haplotype within each etiologic sub-classification. We hypothe-
sized that etiology-based categories defining a trypsin-dependent
pathway would be associated with a larger SPINK1 N34S effect
than those that were trypsin-independent.
Methods
We systematically reviewed the world’s literature on SPINK1
polymorphisms. Only case-control studies were considered. When
possible, subjects were classified according to reported etiology,
with the following categories as presented in Table 1: Alcoholic
chronic pancreatitis (ACP), idiopathic chronic pancreatitis (ICP),
familial/hereditary chronic pancreatitis (FCP) and tropical
pancreatitis (TP). We then conducted a series of meta-analyses
combining subjects within etiology-based sub-classifications as
described below.
Study selection criteria
The literature search and study review was performed by two
separate authors (EA, DCW). Genetic association studies of the
SPINK1 N34S high-risk haplotype in pancreatitis that were
published prior to May 2007 were identified by searching the
PubMed and the EMBASE databases. Search terms included
polymorphism(s), SPINK1, Serine Protease Inhibitor Kazal type 1, PSTI,
N34S and pancreatitis. The reference list of citations in the identified
publications was reviewed to identify additional published articles
not indexed by the major databases. Genetic association studies
that reported the frequency of the SPINK1 N34S high-risk
haplotype in patients with acute and/or chronic pancreatitis and
in a control population were selected. When more than one
published report used data from the same case and control
population, we included only the largest study with extractable
data in the meta-analysis. Corresponding authors were contacted
in some cases to clarify issues of possible data duplication. Only
studies that used validated genotyping methods, such as direct
gene sequencing, polymerase chain reaction paired with restricted
fragment length polymorphism and denaturing gradient gel
electrophoresis, were included. Studies based on linkage results
(pedigree studies), case reports, editorials, review articles and
studies published in a language other than English were excluded.
Data Abstraction
Data abstraction was performed by two separate authors (EA,
CC) and differences were resolved by discussion. The data
elements included the first author, journal, year of publication,
country of origin, racial background of the study population (when
mentioned), demographics, reported etiology of CP (alcoholic,
idiopathic, familial, tropical, etc) and the number of cases and
controls. Allelic frequency, genotypic distribution and genotyping
methods were recorded. All statistical analysis was based on the
number of alleles–as opposed to number of patients, in order to
better quantify homozygous cases.
Statistical Methods
For each study, we initially evaluated the association of SPINK1
N34S high-risk haplotype with CP separately. A preliminary meta-
analysis combining all studies regardless of etiology was conducted.
We then conducted a series of meta-analyses assessing the degree
of risk of various categories of CP with SPINK1 N34S. Effect size
was expressed as an OR with the corresponding 95% confidence
Figure 1. Hypothesis of etiology-defined pathways to pancre-
atic fibrosis. Hypothetical influence diagram illustrating pathologic
pathways linking proximal factor (Factor A and B) to PSC (pancreatic
stellate cell) and fibrosis through multiple steps (e.g. a1, a2, a3).
Etiological factors of type B activate trypsinogen to trypsin, and
therefore their pathologic pathway to the PSC can be interrupted by
SPINK1. Etiological factors of type A are independent of trypsin, and
therefore will not be influenced by variations in SPINK1 expression or
function.
doi:10.1371/journal.pone.0002003.g001
EtOH and SPINK1 Pathways
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interval (CI). Heterogeneity between studies was tested using the
Cochran Q statistic and the I2 value. Because all statistical tests for
heterogeneity are weak, we also included the 95% confidence
interval for I2 [26], which was calculated based on previously
described methods[27]. When heterogeneity was not overtly
evident, we performed the meta-analysis using both the fixed-
effect (Mantel-Hanszel method) and the random-effect models
(DerSimonian and Laird method). When heterogeneity was
present, we only reported the results using the random-effect
model. The Mantel-Hanszel (MH) method was selected over other
fixed-effect methods because of potential small sample sizes of
mutation carriers. An I2 value of 50 was considered the threshold,
above which studies were considered too heterogeneous to be
combined. The Haldane continuity correction (adding 0.5 to each
cell) was used if the quantity of N34S-containing genotypes was
equal to zero in either the cases or the controls. The presence of
publication bias and small study effects were assessed using the
Egger regression asymmetry test for funnel plot and the Begg-
Mazumdar adjusted rank correlation test. Statistical significance
was considered at a p-value of #0.05. In cases where the
polymorphism was not detected in either cases or controls, the
study was omitted from the meta-analyses as it carried a relative
weight of zero. All meta-analyses were conducted using Stata
version 8.2 (Stata, Inc., College Station, Texas) and Comprehen-
sive Meta-Analysis version 2.0 (Biostat Inc. Englewood, New
Jersey).
Table 1. Case control studies considered for inclusion in the meta-analyses and patient subclassification within each study.
Author Year Journal Genotyping Method Population ACP ICP FCP TCP
Chen et al[13] 2000 J Med Genet PCR-DGGE France Excluded*
Witt et al[15] 2000 Nat Gen Direct sequencing Germany - Austria +
Pfutzer et al[14] 2000 Gastro Direct sequencing USA - Europac + +
Plendl et al[46] 2001 Am J Med Gen PCR-RFLP Germany +
Witt et al[47] 2001 JAMA Direct sequencing UK –Germany
-Switzerland
+
Rossi et al[30] 2001 Pancreatology Direct sequencing Bangladesh Excluded**
Chen et al[48] 2001 Gastro PCR-DGGE France +
Kaneko et al[49] 2001 J Hum Genet Direct sequencing+RFLP Japan +
Threadgold et al[50] 2002 Gut Direct sequencing+RFLP Europac + + +
Chandak et al[51] 2002 J Med Genet Direct sequencing India +
Drenth et al[52] 2002 Gut Direct sequencing Netherlands + + +
Bhatia et al[53] 2002 Gastro Direct sequencing India +
Hassan et al[54] 2002 Am J Hum Gen PCR-RFLP Bangladesh - India +
Schneider et al[55] 2002 Gastro Direct sequencing Bangladesh +
Audrezet et al[56] 2002 Eur J Hum Gen PCR-DGGE France +
Truninger et al[57] 2002 Am J Gastro Direct sequencing Europe +
Schneider et al[58] 2003 Dig Dis Sci Direct sequencing USA +
Gomez-Lira et al[59] 2003 Eur J Hum Gen Direct sequencing Italy +
Perri et al[60] 2003 Eur J Hum Gen Direct sequencing Italy +
Bernardino et al[32]N 2003 JOP PCR-RFLP Brazil + + +
Matsubayashi et al[61] 2003 Cancer Biol Ther PCR-RFLP USA +
Chandak et al[62] 2004 Gut Direct sequencing India + + +
Lempinen et al[63] 2005 Scand J Gastro Direct sequencing Finland + +
Kume et al[29] 2005 Pancreatology Direct sequencing Japan Excluded***
Lee et al[64] 2005 Dig Dis Sci PCR-RFLP Korea +
Keiles et al[28] 2006 Pancreas Direct sequencing USA Excluded*
Shimosegawa et al[65] 2006 J Gastro Hepatol PCR-RFLP Japan + + +
S-Tomaszewska[66]NN 2006 J Pediatr Gastroenterol
Nutr
PCR-RFLP Poland
Tzetis et al[67] 2007 Clin Genet PCR-DGGE Greece +
Masamune et al [31] 2007 J Gastroenterol Direct sequencing Japan Excluded****
*Prevalence of the N34S polymorphism was not reported in the control population.
**Data duplicated in Schneider et al [55].
***Data duplicated in Shimosegawa et al [65].
****Data duplicated in Kume et al[29].
NDropped from the analysis because it did not identify the N34S polymorphism in either the cases or the controls therefore resulting in a null relative weight.
NNUnable to subclassify patients into the mentioned categories due to missing data.
PCR: Polymerase Chain Reaction, RFLP: Restricted Fragment Length Polymorphism, DGGE: Denaturing Gradient Gel Electrophoresis.
doi:10.1371/journal.pone.0002003.t001
EtOH and SPINK1 Pathways
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Results
Figure 2 is a flow diagram illustrating the studies included.
Thirty case-control studies evaluating the association of the
SPINK1 N34S polymorphism with CP were identified (Table 1).
Two studies were excluded because the prevalence of the
polymorphism was not reported in the control population
[13,28]. An additional three studies were excluded due to data
duplication in other publications [29,30,31]. Additionally, The
report by Bernardino et al [32] was excluded from the analysis
because it did not identify the N34S polymorphism in either cases
or controls. A total of 24 studies were therefore evaluated.
Chronic Pancreatitis–All etiologies combined
Figure 3 summarizes the results of the initial meta-analysis with
all etiologies of CP combined. The total number of patients from
these studies was 2,421 with 4,857 controls. The mutation was
detected in 469 of 4,842 patient alleles and in 96 of 9,714 control
alleles. Significant heterogeneity was detected (Q=41.05, df = 23,
p = 0.01, I2 = 43.97%). The random effect model showed a
combined OR of 11.00 (95% C.I. = 7.59–15.93). Both the Egger
and the Begg-Mazumdar tests were not statistically significant with
p= 0.65 and p= 0.94 respectively.
Alcoholic Chronic Pancreatitis
We identified patients with alcoholic CP from 9 studies (737
patients, 2,033 controls). Overall, alcohol was the etiologic factor
leading to chronic pancreatitis in 31% of the patients that we were
able to classify. Six of nine studies failed to identify a statistically
significant association between the SPINK1 N34S polymorphism
and alcoholic CP. The SPINK1 N34S high-risk haplotype was
reported in 49 of 1,474 patient alleles and in 37 of 4,066 control
alleles. There was no heterogeneity detected (Q=7.36, df = 8,
p = 0.50, I2 = 0%). Both the fixed and the random-effect model
showed a pooled OR of 4.98 (95% C.I. = 3.16–7.85)–the lowest
among the different categories that we analyzed. Figure 4
summarizes the meta-analysis results pertaining to patients with
alcoholic CP.
Tropical Chronic Pancreatitis
Four studies assessed patients with tropical pancreatitis (351
patients, 973 controls). The high-risk haplotype was detected in
168 of 702 patient alleles and in 44 of 1,946 control alleles. The
heterogeneity testing showed Q=5.72, df = 3, p = 0.13,
I2 = 47.56%. The pooled OR calculated using the random-effect
model was 19.15 (95% C.I. = 8.83–41.56). Figure 5 summarizes
the meta-analysis results pertaining to patients with tropical
pancreatitis.
Idiopathic Chronic Pancreatitis
Fourteen studies were included in this analysis (963 patients,
3,015 controls), only two of which did not detect a statistically
significant association with SPINK1 N34S (figure 6). The
Cochran’s Q statistics was calculated at 20.86 with a p value of
0.08 and an I2 of 37.98%. The pooled OR was 14.97 (95%
C.I. = 9.09–24.67).
Figure 2. Flow diagram of the studies included in the meta-analysis. * The report by Bernardino et al was excluded from the meta-analysis
because it did not detect the N34S haplotype in neither the cases nor the controls and was therefore assigned a weight of zero.
doi:10.1371/journal.pone.0002003.g002
EtOH and SPINK1 Pathways
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Figure 3. Meta-analysis results for chronic pancreatitis all etiologies combined based on allelic frequency. Heterogeneity testing: Q-
value = 41.05, df = 23, p = 0.01, I2 = 43.97 (95% CI: 10.56–64.90).
doi:10.1371/journal.pone.0002003.g003
Figure 4. Meta-analysis results for alcoholic chronic pancreatitis based on allelic frequency. Heterogeneity testing: Q-value= 7.36, df = 8,
p = 0.5, I2 = 0 (95% CI: 0.00–62.01).
doi:10.1371/journal.pone.0002003.g004
Figure 5. Meta-analysis results for tropical pancreatitis based on allelic frequency. Heterogeneity testing: Q-value= 5.72, df = 3, p = 0.13,
I2 = 47.56 (95% CI: 20.96–78.99).
doi:10.1371/journal.pone.0002003.g005
EtOH and SPINK1 Pathways
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Familial and Hereditary Chronic Pancreatitis
Six studies (249 patients, 955 controls) were analyzed.
Significant heterogeneity was detected by the Cochran Q statistic
(Q=26, df = 5, p = 0.00). Additionally, the I-squared value was
80.94%. Due to the high degree of heterogeneity, these studies
were not combined.
Discussion
As stated in a recent article on meta-analysis: ‘‘It is well
appreciated now that besides estimating summary effects, estima-
tion and, if possible, explanation, of the between-study heteroge-
neity is a very important goal for meta-analysis’’[24]. Furthermore,
the article goes on to state that ‘‘in the presence of between-study
heterogeneity in the genetic effects, there may be important
implications for the interpretation of the results’’. The aim of the
current study was to understand the associations between alcohol,
the high-risk SPINK1 N34S haplotype, and CP, and to assess the
strength of any association using etiology-based classifications from
previously reported studies using meta-analyses. As expected
[20,21], we observed wide variation in ORs among small studies
which was reflected in the global meta-analyses results (Figure 3).
Stratifying subjects by commonly reported etiologies and perform-
ing subset meta-analysis to determine the specific effects of SPINK1
N34S in subpopulations, in some cases, revealed low variance. This
finding suggests that these subpopulations are associated with more
homogeneous pathological mechanisms. The different ORs and,
occasionally, non-overlapping CIs (e.g. alcohol versus idiopathic,
tropical etiologies) suggest that the CP syndrome encompasses
several patient subpopulations, and may indicate that the pathologic
pathway linking the proximal etiology to the PSCs in fibrosing CP
are regulated to different degrees by the activity of SPINK1, as
envisioned in Figure 1.
When meta-analysis is applied to complex genetic syndromes,
the measured effect size of a genetic variable between studies is
often widely discrepant [20,21]. A way to interpret the observation
that very large effect sizes in small genetic studies are often not
‘‘reproducible’’ in subsequent studies has been attributed to a
combination of false-positive findings (e.g. related to multiple
testing without correction) and publication bias toward reports
with large effect sizes.
Another potential explanation is that there are multiple sub-
populations with different complex, multi-step etiologic pathways
that all lead to the same phenotype (e.g. end-stage organ fibrosis).
Thus, a genetic factor that is critical in one etiologic pathway will
only be shown to have a large effect size in populations in which
that pathways dominates [25,33]. In other populations, in which
the dominant etiological pathway is independent of the gene
variant in question, the measured effect size of the genetic variant
may be small.
Alcohol is a toxin that damages the pancreas by altering key
regulatory processes, causing direct injury to acinar cells and
driving stellate cells to produce fibrosis. Specifically, studies have
shown that alcohol can act directly on the brainstem [34], acinar
cells [35], immune system [36], and PSCs [37]. The association of
SPINK1 N34S with the risk of alcoholic CP was significant, but the
lowest of the subgroups. This observation suggests that while a
portion of the insult may be associated with premature trypsinogen
activation, alcohol’s primary effects seem to be via SPINK1-
independent pathways (similar to Factor A in Figure 1), and
largely through the direct effects on the immune system and
stellate cells, as has been demonstrated in animal experiments
[37,38,39].
The pathway leading from an unknown factor in tropical
pancreatitis to PSC activation and fibrosis is more strongly affected
by SPINK1 N34S then was seen in alcoholic CP. Although the
proximal, presumably trypsin-associated factors are unknown,
Mahurkar and colleagues have recently reported a higher
incidence of mutations in the cathepsin B gene (CTSB) in patients
with TP than controls [40]. Cathepsin B is a lysosomal enzyme
present in pancreatic acinar cells that appears to be important in
protecting the pancreas from premature trypsinogen activation
[41,42], suggesting that CTSB mutations may increase the risk of
inappropriate trypsin activity within the acinar cells. This may be
one of several critical factors contributing to the etiology of TP.
Patients with idiopathic CP had a significant association with
the SPINK1 N34S polymorphism as evidenced by a pooled OR of
14.66. Noone et al. reported a high incidence of CFTR mutations
in patients with ICP and further demonstrated that the combined
risk of CFTR mutations and SPINK1 polymorphisms was
multiplicative rather than additive [43]. Although the various
etiologies of idiopathic CP are largely unknown, the significant
Figure 6. Meta-analysis results for idiopathic chronic pancreatitis based on allelic frequency. Heterogeneity testing: Q-value= 20.86,
df = 13, p = 0.08, I2 = 37.98 (95% CI: 0.00–65.00).
doi:10.1371/journal.pone.0002003.g006
EtOH and SPINK1 Pathways
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enrichment of this group with subjects carrying PRSS1 and CFTR
mutations and the large effect of SPINK1 polymorphisms with
progression to CP is consistent with our proposed model. Of note,
the highest reported OR of any study (OR=,80) was that of Witt
et al that was conducted in a relatively homogenous group of
children with early onset idiopathic CP where few, if any,
environmental exposures played a role, especially tobacco smoking
and alcohol [15]. Thus, the high OR reflected an enrichment of
the pathway that is most strongly regulated by SPINK1 rather
than the random effects of chance.
The risk of familial and hereditary CP is strongly associated with
SPINK1 N34S, but these data should be interpreted with caution.
Hereditary pancreatitis is an autosomal dominant disorder with
very high penetrance that is caused by gain-of-function mutation
in the cationic trypsinogen gene [10]. The etiology of hereditary
pancreatitis is unequivocally linked to trypsin-associated pathway
of recurrent acute pancreatitis leading to CP, but the effect is to
such a degree that normal expression of SPINK is not sufficient to
prevent it. On the other hand, a major proportion of familial
chronic pancreatitis that is not autosomal dominant is associated
with multiple family members with homozygous SPINK1 muta-
tions. In this case, the etiology-based classification system is biased
toward an association with SPINK1. These factors likely contribute
to the high heterogeneity of effects in this classification.
The current study has several limitations. One of the challenges
in understanding CP in human subjects is distinguishing trypsin-
dependent and trypsin-independent pathways in CP from the
central role of trypsin in acute pancreatitis. Indeed, AP may be
necessary to initiate CP by activating the immune system within
the pancreas (including PSCs), thereby initiating the fibrosing
process [44,45]. Thus, although CP is driven by trypsin-depended
and trypsin- independent factors, the fact that an individual is
initially susceptible to the first episode of AP may blur the
distinction between trypsin-dependent and trypsin-independent
pathways to CP. Another limitation is that the published reports
did not include or classify pancreatic fibrosis caused by
autoimmune pancreatitis or pancreatic cancer, which, because
they are thought to be trypsin-independent, would have been an
important comparison group for SPINK1 N34S effects. Further-
more, the effect of ethnicity and race was usually not reported,
although the country of origin was available (Table 1) and the
etiologies of interest were clearly reported. Genetic polymorphisms
often vary by race or ethnicity. Further studies are warranted to
more thoroughly evaluate racial and/or ethnic variation in SPINK
polymorphisms. Another limitation relies in the fact that
classification of the patients into etiology-based subgroups was
carried based on the etiologies listed in the manuscripts included in
the analysis. It is unlikely that all twenty-four centers used the same
criteria to diagnose and categorize these patients and therefore
variations in the diagnostic criteria may explain some of the
heterogeneity observed. Furthermore, a certain degree of
misclassification may have occurred as a result and there is
considerable residual heterogeneity beyond what the etiologic
grouping can explain. Additionally, the presence of potential
confounding variables or modifying factors could not be
completely ruled out due to the limited amount of information
and data assessing such factors in each study. Despite these
challenges, clear differences in the effect of SPINK1 in different
etiologies were observed.
In conclusion, meta-analysis of association studies examining
the SPINK1 N34S polymorphism in CP confirms a significant
overall pathologic association, although the reported effect size
varies significantly depending on the etiology of CP. Modeling CP
as a complex syndrome resulting from various pathogenic
pathways with or without recurrent trypsinogen activation allows
for the direct assessment of the effect of SPINK1 polymorphisms in
the development of CP. While the subgroup analysis needs to be
interpreted with caution, our results suggest that much of the
variance in reported ORs between small studies of candidate genes
in complex disorders may be attributed to a mixture of multiple
etiologic pathways leading to a single clinical endpoint (e.g. organ
fibrosis in CP). Alcohol appears to drive fibrosis in alcoholic CP
primarily through a trypsin-independent pathway as reflected by
the significantly lower association of SPINK1 N34S with this
etiology. Additional studies are warranted to further assess the
presence of any confounding or modifying factors and to elucidate
the various pathophysiologic mechanisms involved and their
implications in the etiology of CP.
Acknowledgments
We thank Drs. Robert Ferrell, Nevin Oruc and Janette Lamb for helpful
review and discussions.
Author Contributions
Conceived and designed the experiments: DW EA. Performed the
experiments: EA CC. Analyzed the data: DW EA CC MB GP. Wrote
the paper: DW EA JG.
References
1. Sarles H, Adler G, Dani R, Frey C, Gullo L, et al. (1989) The pancreatitis
classification of Marseilles-Rome 1988. Scand J Gastroenterol 24: 641–642.
2. Whitcomb DC (2006) Clinical practice. Acute pancreatitis. N Engl J Med 354:
2142–2150.
3. Etemad B, Whitcomb DC (2001) Chronic pancreatitis: diagnosis, classification,
and new genetic developments. Gastroenterology 120: 682–707.
4. Steer ML, Waxman I, Freedman S (1995) Chronic pancreatitis. N Engl J Med
332: 1482–1490.
5. Warshaw AL, Banks PA, Fernandez-Del Castillo C (1998) AGA technical
review: treatment of pain in chronic pancreatitis. Gastroenterology 115:
765–776.
6. Bachem MG, Zhou Z, Zhou S, Siech M (2006) Role of stellate cells in pancreatic
fibrogenesis associated with acute and chronic pancreatitis. J Gastroenterol
Hepatol 21 Suppl 3: S92–96.
7. Omary MB, Lugea A, Lowe AW, Pandol SJ (2007) The pancreatic stellate cell: a
star on the rise in pancreatic diseases. J Clin Invest 117: 50–59.
8. Lankisch PG, Lowenfels AB, Maisonneuve P (2002) What is the risk of alcoholic
pancreatitis in heavy drinkers? Pancreas 25: 411–412.
9. Yadav D, Papachristou GI, Whitcomb DC (2007) Alcohol-associated pancre-
atitis. Gastroenterol Clin North Am 36: 219–238, vii.
10. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, et al.
(1996) Hereditary pancreatitis is caused by a mutation in the cationic
trypsinogen gene. Nat Genet 14: 141–145.
11. Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, et al. (1998)
Relation between mutations of the cystic fibrosis gene and idiopathic
pancreatitis. N Engl J Med 339: 653–658.
12. Sharer N, Schwarz M, Malone G, Howarth A, Painter J, et al. (1998) Mutations
of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med
339: 645–652.
13. Chen JM, Mercier B, Audrezet MP, Ferec C (2000) Mutational analysis of the
human pancreatic secretory trypsin inhibitor (PSTI) gene in hereditary and
sporadic chronic pancreatitis. J Med Genet 37: 67–69.
14. Pfutzer RH, Barmada MM, Brunskill AP, Finch R, Hart PS, et al. (2000)
SPINK1/PSTI polymorphisms act as disease modifiers in familial and idiopathic
chronic pancreatitis. Gastroenterology 119: 615–623.
15. Witt H, Luck W, Hennies HC, Classen M, Kage A, et al. (2000) Mutations in
the gene encoding the serine protease inhibitor, Kazal type 1 are associated with
chronic pancreatitis. Nat Genet 25: 213–216.
16. Khalid A, Finkelstein S, Thompson B, Kelly L, Hanck C, et al. (2006) A 93 year
old man with the PRSS1 R122H mutation, low SPINK1 expression, and no
pancreatitis: insights into phenotypic non-penetrance. Gut 55: 728–731.
17. Lasson A, Borgstrom A, Ohlsson K (1986) Elevated pancreatic secretory trypsin
inhibitor levels during severe inflammatory disease, renal insufficiency, and after
various surgical procedures. Scand J Gastroenterol 21: 1275–1280.
18. Ogawa M (1988) Pancreatic secretory trypsin inhibitor as an acute phase
reactant. Clin Biochem 21: 19–25.
EtOH and SPINK1 Pathways
PLoS ONE | www.plosone.org 7 April 2008 | Volume 3 | Issue 4 | e2003
19. Whitcomb DC (2002) How to think about SPINK and pancreatitis.
Am J Gastroenterol 97: 1085–1088.
20. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001)
Replication validity of genetic association studies. Nat Genet 29: 306–309.
21. Ioannidis JP, Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG (2003)
Genetic associations in large versus small studies: an empirical assessment.
Lancet 361: 567–571.
22. Trikalinos TA, Ntzani EE, Contopoulos-Ioannidis DG, Ioannidis JP (2004)
Establishment of genetic associations for complex diseases is independent of
early study findings. Eur J Hum Genet 12: 762–769.
23. Lau J, Ioannidis JP, Schmid CH (1998) Summing up evidence: one answer is not
always enough. Lancet 351: 123–127.
24. Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Heterogeneity in meta-
analyses of genome-wide association investigations. PLoS ONE 2: e841.
25. Whitcomb DC, Barmada MM (2007) A systems biology approach to genetic
studies of pancreatitis and other complex diseases. Cell Mol Life Sci.
26. Ioannidis JP, Patsopoulos NA, Evangelou E (2007) Uncertainty in heterogeneity
estimates in meta-analyses. Bmj 335: 914–916.
27. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis.
Stat Med 21: 1539–1558.
28. Keiles S, Kammesheidt A (2006) Identification of CFTR, PRSS1, and SPINK1
mutations in 381 patients with pancreatitis. Pancreas 33: 221–227.
29. Kume K, Masamune A, Mizutamari H, Kaneko K, Kikuta K, et al. (2005)
Mutations in the serine protease inhibitor Kazal Type 1 (SPINK1) gene in
Japanese patients with pancreatitis. Pancreatology 5: 354–360.
30. Rossi L, Pfutzer RH, Parvin S, Ali L, Sattar S, et al. (2001) SPINK1/PSTI
mutations are associated with tropical pancreatitis in Bangladesh. A preliminary
report. Pancreatology 1: 242–245.
31. Masamune A, Kume K, Shimosegawa T (2007) Differential roles of the SPINK1
gene mutations in alcoholic and nonalcoholic chronic pancreatitis.
J Gastroenterol 42 Suppl 17: 135–140.
32. Bernardino AL, Guarita DR, Mott CB, Pedroso MR, Machado MC, et al.
(2003) CFTR, PRSS1 and SPINK1 mutations in the development of pancreatitis
in Brazilian patients. Jop 4: 169–177.
33. Whitcomb DC, Aoun E, Vodovotz Y, Clermont G, Barmada MM (2005)
Evaluating disorders with a complex genetics basis. the future roles of meta-
analysis and systems biology. Dig Dis Sci 50: 2195–2202.
34. Deng X, Wood PG, Eagon PK, Whitcomb DC (2004) Chronic alcohol-induced
alterations in the pancreatic secretory control mechanisms. Dig Dis Sci 49:
805–819.
35. Katz M, Carangelo R, Miller LJ, Gorelick F (1996) Effect of ethanol on
cholecystokinin-stimulated zymogen conversion in pancreatic acinar cells.
Am J Physiol 270: G171–175.
36. Whitcomb DC (2004) Value of genetic testing in the management of
pancreatitis. Gut 53: 1710–1717.
37. Apte MV, Phillips PA, Fahmy RG, Darby SJ, Rodgers SC, et al. (2000) Does
alcohol directly stimulate pancreatic fibrogenesis? Studies with rat pancreatic
stellate cells. Gastroenterology 118: 780–794.
38. Fortunato F, Deng X, Gates LK, McClain CJ, Bimmler D, et al. (2006)
Pancreatic response to endotoxin after chronic alcohol exposure: switch from
apoptosis to necrosis? Am J Physiol Gastrointest Liver Physiol 290: G232–241.
39. Wang YL, Hu R, Lugea A, Gukovsky I, Smoot D, et al. (2006) Ethanol feeding
alters death signaling in the pancreas. Pancreas 32: 351–359.
40. Mahurkar S, Idris MM, Reddy DN, Bhaskar S, Rao GV, et al. (2006)
Association of cathepsin B gene polymorphisms with tropical calcific
pancreatitis. Gut 55: 1270–1275.
41. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger M, et al.
(2000) Role of cathepsin B in intracellular trypsinogen activation and the onset of
acute pancreatitis. J Clin Invest 106: 773–781.
42. Szilagyi L, Kenesi E, Katona G, Kaslik G, Juhasz G, et al. (2001) Comparative
in vitro studies on native and recombinant human cationic trypsins. Cathepsin B
is a possible pathological activator of trypsinogen in pancreatitis. J Biol Chem
276: 24574–24580.
43. Noone PG, Zhou Z, Silverman LM, Jowell PS, Knowles MR, et al. (2001) Cystic
fibrosis gene mutations and pancreatitis risk: relation to epithelial ion transport
and trypsin inhibitor gene mutations. Gastroenterology 121: 1310–1319.
44. Schneider A, Whitcomb DC (2002) Hereditary pancreatitis: a model for
inflammatory diseases of the pancreas. Best Pract Res Clin Gastroenterol 16:
347–363.
45. Whitcomb DC (2004) Mechanisms of disease: Advances in understanding the
mechanisms leading to chronic pancreatitis. Nat Clin Pract Gastroenterol
Hepatol 1: 46–52.
46. Plendl H, Siebert R, Steinemann D, Grote W (2001) High frequency of the
N34S mutation in the SPINK1 gene in chronic pancreatitis detected by a new
PCR-RFLP assay. Am J Med Genet 100: 252–253.
47. Witt H, Luck W, Becker M, Bohmig M, Kage A, et al. (2001) Mutation in the
SPINK1 trypsin inhibitor gene, alcohol use, and chronic pancreatitis. Jama 285:
2716–2717.
48. Chen JM, Mercier B, Audrezet MP, Raguenes O, Quere I, et al. (2001)
Mutations of the pancreatic secretory trypsin inhibitor (PSTI) gene in idiopathic
chronic pancreatitis. Gastroenterology 120: 1061–1064.
49. Kaneko K, Nagasaki Y, Furukawa T, Mizutamari H, Sato A, et al. (2001)
Analysis of the human pancreatic secretory trypsin inhibitor (PSTI) gene
mutations in Japanese patients with chronic pancreatitis. J Hum Genet 46:
293–297.
50. Threadgold J, Greenhalf W, Ellis I, Howes N, Lerch MM, et al. (2002) The
N34S mutation of SPINK1 (PSTI) is associated with a familial pattern of
idiopathic chronic pancreatitis but does not cause the disease. Gut 50: 675–681.
51. Chandak GR, Idris MM, Reddy DN, Bhaskar S, Sriram PV, et al. (2002)
Mutations in the pancreatic secretory trypsin inhibitor gene (PSTI/SPINK1)
rather than the cationic trypsinogen gene (PRSS1) are significantly associated
with tropical calcific pancreatitis. J Med Genet 39: 347–351.
52. Drenth JP, te Morsche R, Jansen JB (2002) Mutations in serine protease
inhibitor Kazal type 1 are strongly associated with chronic pancreatitis. Gut 50:
687–692.
53. Bhatia E, Choudhuri G, Sikora SS, Landt O, Kage A, et al. (2002) Tropical
calcific pancreatitis: strong association with SPINK1 trypsin inhibitor mutations.
Gastroenterology 123: 1020–1025.
54. Hassan Z, Mohan V, Ali L, Allotey R, Barakat K, et al. (2002) SPINK1 is a
susceptibility gene for fibrocalculous pancreatic diabetes in subjects from the
Indian subcontinent. Am J Hum Genet 71: 964–968.
55. Schneider A, Suman A, Rossi L, Barmada MM, Beglinger C, et al. (2002)
SPINK1/PSTI mutations are associated with tropical pancreatitis and type II
diabetes mellitus in Bangladesh. Gastroenterology 123: 1026–1030.
56. Audrezet MP, Chen JM, Le Marechal C, Ruszniewski P, Robaszkiewicz M, et
al. (2002) Determination of the relative contribution of three genes-the cystic
fibrosis transmembrane conductance regulator gene, the cationic trypsinogen
gene, and the pancreatic secretory trypsin inhibitor gene-to the etiology of
idiopathic chronic pancreatitis. Eur J Hum Genet 10: 100–106.
57. Truninger K, Witt H, Kock J, Kage A, Seifert B, et al. (2002) Mutations of the
serine protease inhibitor, Kazal type 1 gene, in patients with idiopathic chronic
pancreatitis. Am J Gastroenterol 97: 1133–1137.
58. Schneider A, Pfutzer RH, Barmada MM, Slivka A, Martin J, et al. (2003)
Limited contribution of the SPINK1 N34S mutation to the risk and severity of
alcoholic chronic pancreatitis: a report from the United States. Dig Dis Sci 48:
1110–1115.
59. Gomez-Lira M, Bonamini D, Castellani C, Unis L, Cavallini G, et al. (2003)
Mutations in the SPINK1 gene in idiopathic pancreatitis Italian patients.
Eur J Hum Genet 11: 543–546.
60. Perri F, Piepoli A, Stanziale P, Merla A, Zelante L, et al. (2003) Mutation
analysis of the cystic fibrosis transmembrane conductance regulator (CFTR)
gene, the cationic trypsinogen (PRSS1) gene, and the serine protease inhibitor,
Kazal type 1 (SPINK1) gene in patients with alcoholic chronic pancreatitis.
Eur J Hum Genet 11: 687–692.
61. Matsubayashi H, Fukushima N, Sato N, Brune K, Canto M, et al. (2003)
Polymorphisms of SPINK1 N34S and CFTR in patients with sporadic and
familial pancreatic cancer. Cancer Biol Ther 2: 652–655.
62. Chandak GR, Idris MM, Reddy DN, Mani KR, Bhaskar S, et al. (2004) Absence
of PRSS1 mutations and association of SPINK1 trypsin inhibitor mutations in
hereditary and non-hereditary chronic pancreatitis. Gut 53: 723–728.
63. Lempinen M, Paju A, Kemppainen E, Smura T, Kylanpaa ML, et al. (2005)
Mutations N34S and P55S of the SPINK1 gene in patients with chronic
pancreatitis or pancreatic cancer and in healthy subjects: a report from Finland.
Scand J Gastroenterol 40: 225–230.
64. Lee KH, Ryu JK, Yoon WJ, Lee JK, Kim YT, et al. (2005) Mutation analysis of
SPINK1 and CFTR gene in Korean patients with alcoholic chronic pancreatitis.
Dig Dis Sci 50: 1852–1856.
65. Shimosegawa T, Kume K, Masamune A (2006) SPINK1 gene mutations and
pancreatitis in Japan. J Gastroenterol Hepatol 21 Suppl 3: S47–51.
66. Sobczynska-Tomaszewska A, Bak D, Oralewska B, Oracz G, Norek A, et al.
(2006) Analysis of CFTR, SPINK1, PRSS1 and AAT mutations in children with
acute or chronic pancreatitis. J Pediatr Gastroenterol Nutr 43: 299–306.
67. Tzetis M, Kaliakatsos M, Fotoulaki M, Papatheodorou A, Doudounakis S, et al.
(2007) Contribution of the CFTR gene, the pancreatic secretory trypsin inhibitor
gene (SPINK1) and the cationic trypsinogen gene (PRSS1) to the etiology of
recurrent pancreatitis. Clin Genet 71: 451–457.
EtOH and SPINK1 Pathways
PLoS ONE | www.plosone.org 8 April 2008 | Volume 3 | Issue 4 | e2003
